Phenotypes Associated with This Genotype

Genotype
MGI:5766492

• Allelic Composition: Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop; Tg(tetO-NPM1/ALK,-luc)2Gde/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:160236 )

• mice die within a mean latency of 4 weeks when dox is removed at the newborn stage

embryonic lethality, complete penetrance ( J:160236 )

• embryonic lethality is seen in the absence of doxycycline (dox)

immune system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

enlarged lymph nodes ( J:160236 )

• generalized lymphadenopathy in mice when dox is removed in newborns

growth/size/body

postnatal growth retardation ( J:160236 )

• mice are growth retarded when dox is removed in newborns

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

hematopoietic system

enlarged spleen ( J:160236 )

• splenomegaly in mice when dox is removed in newborns

integument

abnormal skin morphology ( J:160236 )

• induction of transgene expression by removal of dox in newborns results in the development of a skin disease affecting the snout and paws, first detectable at 3 weeks of age

abnormal dermal layer morphology ( J:160236 )

• lymphomatous infiltration is sometimes seen in the dermis below the keratoacanthoma-like lesions

epidermal hyperplasia ( J:160236 )

• mice exhibit skin nodules of a hyperplasia of the epidermis when dox is removed at the newborn stage, suggesting a keratoacanathoma-like lesion

• mice that are moribund with tumors and treated with dox for 12 days to suppress transgene expression exhibit a clearing of skin lesions and regrowth of hair within 3 weeks

• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in a progressive clearing of skin lesions

neoplasm

increased leukemia incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

increased B cell derived lymphoma incidence ( J:160236 )

• mice develop aggressive lymphoma/leukemia when dox is removed in newborns

• lymphoma/leukemia are derived from B cells

• transplantation of mutant bone marrow into recipient mice results in the development of B-cell lymphoma without skin lesions

• mice that are moribund with tumors and treated with dox for 12 days exhibit tumor regression

• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in tumor regression

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
non-Hodgkin lymphoma		DOID:0060060	OMIM:605027	J:160236